The evolution of thalidomide and its IMiD derivatives as anticancer agents
1
Celgene Corporation, Warren, USA
|
2
the Department of Cellular & Molecular Medicine, St George's Hospital Medical School, Cranmer Terrace, London, UK
|
Publication type: Journal Article
Publication date: 2004-04-01
scimago Q1
wos Q1
SJR: 24.378
CiteScore: 103.8
Impact factor: 66.8
ISSN: 1474175X, 14741768
DOI:
10.1038/nrc1323
PubMed ID:
15057291
General Environmental Science
General Earth and Planetary Sciences
Abstract
Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects. Remarkably, thalidomide was subsequently discovered to have anti-inflammatory and anti-angiogenic properties, and was identified as an effective treatment for multiple myeloma. A series of immunomodulatory drugs — created by chemical modification of thalidomide — have been developed to overcome the original devastating side effects. Their powerful anticancer properties mean that these drugs are now emerging from thalidomide's shadow as useful anticancer agents.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
|
|
|
Blood
21 publications, 3.19%
|
|
|
Bioorganic and Medicinal Chemistry Letters
12 publications, 1.82%
|
|
|
Leukemia and Lymphoma
12 publications, 1.82%
|
|
|
Clinical Cancer Research
11 publications, 1.67%
|
|
|
Journal of Clinical Oncology
10 publications, 1.52%
|
|
|
Future Oncology
8 publications, 1.21%
|
|
|
British Journal of Haematology
8 publications, 1.21%
|
|
|
Bioorganic and Medicinal Chemistry
7 publications, 1.06%
|
|
|
Seminars in Oncology
7 publications, 1.06%
|
|
|
Cancer
7 publications, 1.06%
|
|
|
Scientific Reports
6 publications, 0.91%
|
|
|
Leukemia
6 publications, 0.91%
|
|
|
Annals of Hematology
6 publications, 0.91%
|
|
|
European Journal of Medicinal Chemistry
6 publications, 0.91%
|
|
|
Clinical Lymphoma & Myeloma
6 publications, 0.91%
|
|
|
Seminars in Hematology
6 publications, 0.91%
|
|
|
Expert Review of Anticancer Therapy
6 publications, 0.91%
|
|
|
Expert Review of Hematology
6 publications, 0.91%
|
|
|
Expert Opinion on Investigational Drugs
6 publications, 0.91%
|
|
|
Expert Opinion on Pharmacotherapy
6 publications, 0.91%
|
|
|
Chemical and Pharmaceutical Bulletin
5 publications, 0.76%
|
|
|
Nature Communications
5 publications, 0.76%
|
|
|
Cancers
4 publications, 0.61%
|
|
|
Blood Reviews
4 publications, 0.61%
|
|
|
Seminars in Cancer Biology
4 publications, 0.61%
|
|
|
Bioorganic Chemistry
4 publications, 0.61%
|
|
|
Journal of Enzyme Inhibition and Medicinal Chemistry
4 publications, 0.61%
|
|
|
Cancer Research
4 publications, 0.61%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
4 publications, 0.61%
|
|
|
5
10
15
20
25
|
Publishers
|
20
40
60
80
100
120
140
160
180
200
|
|
|
Elsevier
184 publications, 27.92%
|
|
|
Springer Nature
88 publications, 13.35%
|
|
|
Taylor & Francis
76 publications, 11.53%
|
|
|
Wiley
58 publications, 8.8%
|
|
|
American Society of Hematology
24 publications, 3.64%
|
|
|
American Chemical Society (ACS)
19 publications, 2.88%
|
|
|
American Association for Cancer Research (AACR)
18 publications, 2.73%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
12 publications, 1.82%
|
|
|
Royal Society of Chemistry (RSC)
12 publications, 1.82%
|
|
|
SAGE
11 publications, 1.67%
|
|
|
MDPI
11 publications, 1.67%
|
|
|
Frontiers Media S.A.
11 publications, 1.67%
|
|
|
American Society of Clinical Oncology (ASCO)
11 publications, 1.67%
|
|
|
Hindawi Limited
9 publications, 1.37%
|
|
|
Pharmaceutical Society of Japan
8 publications, 1.21%
|
|
|
Oxford University Press
6 publications, 0.91%
|
|
|
Spandidos Publications
5 publications, 0.76%
|
|
|
Public Library of Science (PLoS)
5 publications, 0.76%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
4 publications, 0.61%
|
|
|
Cold Spring Harbor Laboratory
4 publications, 0.61%
|
|
|
Bentham Science Publishers Ltd.
3 publications, 0.46%
|
|
|
Impact Journals
3 publications, 0.46%
|
|
|
The Japan Institute of Heterocyclic Chemistry
3 publications, 0.46%
|
|
|
Annual Reviews
3 publications, 0.46%
|
|
|
Cambridge University Press
3 publications, 0.46%
|
|
|
American Society for Clinical Investigation
2 publications, 0.3%
|
|
|
Portland Press
2 publications, 0.3%
|
|
|
Baishideng Publishing Group
2 publications, 0.3%
|
|
|
Moffitt Cancer Center
2 publications, 0.3%
|
|
|
20
40
60
80
100
120
140
160
180
200
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
659
Total citations:
659
Citations from 2025:
25
(3.79%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Bartlett J. B., Dredge K., Dalgleish A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents // Nature Reviews Cancer. 2004. Vol. 4. No. 4. pp. 314-322.
GOST all authors (up to 50)
Copy
Bartlett J. B., Dredge K., Dalgleish A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents // Nature Reviews Cancer. 2004. Vol. 4. No. 4. pp. 314-322.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/nrc1323
UR - https://doi.org/10.1038/nrc1323
TI - The evolution of thalidomide and its IMiD derivatives as anticancer agents
T2 - Nature Reviews Cancer
AU - Bartlett, J Blake
AU - Dredge, Keith
AU - Dalgleish, Angus G.
PY - 2004
DA - 2004/04/01
PB - Springer Nature
SP - 314-322
IS - 4
VL - 4
PMID - 15057291
SN - 1474-175X
SN - 1474-1768
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2004_Bartlett,
author = {J Blake Bartlett and Keith Dredge and Angus G. Dalgleish},
title = {The evolution of thalidomide and its IMiD derivatives as anticancer agents},
journal = {Nature Reviews Cancer},
year = {2004},
volume = {4},
publisher = {Springer Nature},
month = {apr},
url = {https://doi.org/10.1038/nrc1323},
number = {4},
pages = {314--322},
doi = {10.1038/nrc1323}
}
Cite this
MLA
Copy
Bartlett, J. Blake, et al. “The evolution of thalidomide and its IMiD derivatives as anticancer agents.” Nature Reviews Cancer, vol. 4, no. 4, Apr. 2004, pp. 314-322. https://doi.org/10.1038/nrc1323.